• Anti-HMGB1 Rabbit Monoclonal Antibody Guide

  2026-09-10

  The Anti-HMGB1 Rabbit Monoclonal Antibody (MA3057) provides a research reagent for detecting HMGB1 in human, mouse, and rat samples by Western blot, immunohistochemistry, and flow cytometry. This guide explains how to establish assay controls and optimize handling, while defining the product as research-use only and not validated for diagnostic or therapeutic applications.

• HyperFluor™ 488 Rabbit Anti-Goat IgG (H+L) Antibody

  2026-09-10

  Build sensitive fluorescence workflows for goat primary antibodies across tissue imaging, Western blotting, flow cytometry, and ELISA. This Alexa Fluor 488 conjugated secondary antibody combines H+L recognition with practical signal amplification for studies of hypoxia-linked tissue injury and signaling.

• Docosahexaenoic Acid (DHA) Assay Guide

  2026-09-09

  A scenario-driven guide to using Docosahexaenoic Acid (DHA), SKU C4188, in cell viability, proliferation, and neuroprotection research. It covers formulation, assay controls, interpretation, and practical vendor-selection criteria while distinguishing product specifications from literature evidence.

• Rapamycin (Sirolimus): mTOR Research Guide

  2026-09-09

  Rapamycin, also called Sirolimus, is an FKBP12-dependent mTOR inhibitor with reported biochemical potency near 0.1 nM. This guide connects its product specifications and research applications with evidence on CD24-regulated ectosome formation in B lymphocytes.

• HyperFluor™ 488 Rabbit Anti-Goat IgG (H+L) Antibody

  2026-09-08

  Build sensitive immunofluorescence, Western blot, tissue-staining, and flow cytometry workflows around a spectrally defined Alexa Fluor 488 secondary antibody. This guide translates a hypoxia-injury study into practical controls, optimization screens, and troubleshooting decisions without implying that the featured reagent was used in the original research.

• TPCA-1 Workflow for NF-κB and Cell-Death Research

  2026-09-08

  Use TPCA-1 as a selective IKK-2 inhibitor to separate NF-κB-dependent inflammatory transcription from RIPK1-linked apoptosis and necroptosis. This workflow combines cytokine profiling, pathway readouts, cell-death assays, and practical formulation guidance for inflammation and rheumatoid arthritis research.

• Novel Allosteric PDK4 Inhibitors for Metabolic Disease

  2026-09-07

  Jeon and colleagues identified a new anthraquinone-derived series of allosteric pyruvate dehydrogenase kinase 4 inhibitors, with compound 8c showing an in vitro IC50 of 84 nM and activity across metabolic, allergic, and cancer-related preclinical models. The study combines medicinal chemistry, enzyme assays, pharmacokinetics, animal efficacy testing, cellular phenotyping, and docking to establish a promising scaffold while highlighting the evidence still needed for translation.

• SepM Mutations in S. mutans and Bacterial Competition

  2026-09-07

  Liu et al. linked three sepM missense mutations in clinical Streptococcus mutans isolates with stronger inhibition of Streptococcus gordonii and showed that selected SepM variants bind CSP-21 more strongly under pH-dependent conditions. The study combines clinical isolate phenotyping, Sanger sequencing, expression analysis, recombinant protein work, and binding measurements to connect genotype with a plausible ComDE signaling mechanism.

• HyperFluor™ 488 Rabbit Anti-Goat IgG (H+L) Antibody Workflow

  2026-09-05

  Build sensitive goat-primary detection workflows for immunofluorescence, Western blotting, flow cytometry, and tissue staining with a defined Alexa Fluor 488 signal. This guide translates the PHD2/HIF-1α/EPO findings from a high-altitude hypoxia study into practical assay design, controls, and troubleshooting decisions.

• HyperFluor 488 Goat Anti-Human IgG (H+L) Antibody

  2026-09-04

  Build sensitive human-IgG detection workflows for immunofluorescence, Western blotting, flow cytometry, IHC, and ELISA with one Alexa Fluor 488-labeled secondary. The guide emphasizes variant-panel assay design, species matching, quantitative controls, and practical troubleshooting for translational vaccine research.

• SPP2 as a Negative Regulator of Liver Regeneration

  2026-09-04

  Lin et al. combined transcriptomic discovery with in vivo CRISPR screening to identify SPP2 as a secreted inhibitor of liver regeneration. Genetic loss of Spp2 improved recovery after liver injury, while mechanistic experiments linked its effects to BMP antagonism and interactions with integrin-family receptors.

• YC-1: From Hypoxia Biology to Translational Strategy

  2026-09-03

  YC-1 offers translational researchers a mechanistically rich way to interrogate hypoxia, soluble guanylyl cyclase signaling, tumor vascular biology, and pathway-dependent phenotypes. This article connects its established cancer research utility with emerging neuroinflammation findings while clearly distinguishing evidence from hypothesis.

• Lycopene, ERK, and DON-Induced Gut Barrier Injury

  2026-09-03

  A 2025 study in Antioxidants shows that lycopene protects porcine intestinal epithelial cells from deoxynivalenol-induced barrier disruption, oxidative stress, inflammation, and NLRP3 inflammasome activation. Pharmacological ERK activation weakened this protection, supporting ERK as a functional signaling target while highlighting the limits of translating an in vitro mechanism directly to animal or human toxicology.

• HyperFluor™ 488 Rabbit Anti-Goat IgG Workflow

  2026-09-02

  Build sensitive goat-primary immunostaining workflows for hypoxia, inflammation, and tissue-injury studies with a green-fluorescent secondary antibody. This guide connects the reference study’s lung and kidney readouts with practical choices for immunofluorescence, Western blotting, flow cytometry, and tissue imaging.

• Methylprednisolone Sodium Succinate Research

  2026-09-02

  Methylprednisolone Sodium Succinate is a synthetic corticosteroid for research on glucocorticoid-regulated inflammation, immune-cell behavior, and apoptosis induction in tumor cells. Product specifications and cited spinal cord injury evidence support defined assay benchmarks, but they do not establish a universal clinical treatment protocol.

8514 records 1/568 page Next 12345 下5页 Last page